NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
- None.
- None.
The completion of enrollment in NRx Pharmaceuticals' Phase 2b/3 study for NRX-101 signifies a pivotal moment in the development of treatments for Suicidal Treatment Resistant Bipolar Depression. The slight increase in patient enrollment beyond the original target indicates a strategic move to strengthen the statistical significance of the trial outcomes. This is particularly important in central nervous system (CNS) trials where patient variability can be high and statistical power is crucial for determining efficacy.
The fact that the study has exceeded industry standards with over 94% treatment compliance and concordance rates is noteworthy. In CNS trials, these metrics are critical as they reflect the reliability of the data collected and the uniformity of the assessments across different raters. High concordance rates suggest that the trial's methodology is robust, which may contribute to the credibility of the results once they are published.
The announcement that positive data from this trial will trigger a milestone payment from Alvogen is of particular interest to investors and stakeholders. This indicates a pre-arranged financial agreement contingent on the success of the trial, which could have immediate financial implications for NRx Pharmaceuticals. The responsibility of Alvogen to take on further development and commercialization costs post-trial suggests a transfer of financial burden and potential for revenue generation for NRx Pharmaceuticals.
Furthermore, the Breakthrough Therapy Designation previously awarded by the FDA to NRX-101 can accelerate the development and review process. If the results of the trial are positive, this could potentially lead to a faster path to market, which is a significant advantage in the competitive pharmaceutical industry.
The target market for NRX-101, if approved, represents a significant patient population suffering from Suicidal Treatment Resistant Bipolar Depression. The current standard treatment being electroconvulsive therapy (ECT), an oral medication like NRX-101 could disrupt the market by providing a more accessible and potentially less invasive treatment option. Market adoption could be influenced by factors such as efficacy, safety profile, ease of use and cost, compared to ECT and other treatments.
Understanding the competitive landscape and the unmet needs within the bipolar depression treatment space will be crucial. NRx Pharmaceuticals' positioning of NRX-101 as the 'first and only oral medication' for reduced suicidal ideation in this patient group could be a strong differentiator if the trial results are favorable and the product reaches the market.
- Exceeded originally target enrollment (70) with n=74
- Last patient, last visit expected in approximately six weeks; data to follow shortly thereafter
- Positive data triggers milestone payment from Alvogen, as previously announced.
"To our knowledge, NRX-101 is the first and only oral medication to have demonstrated reduced suicidal ideation in patients with bipolar depression, a lethal disease that claims the lives of one in five who live with it. On the basis of our previous trial, it was awarded Breakthrough Therapy Designation by the FDA and we aim to confirm its effect on depression and suicidal ideation in this trial. We thank our study investigators, dedicated trial sites, and of course, incredible patients," said Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals. "We hope to bring a lifesaving home-use oral medicine to patients whose only currently-approved treatment is electroconvulsive therapy (ECT)."
The Phase 2b/3 trial (www.clinicaltrials.gov NCT 03395392) enrolled 74 patients with suicidal bipolar depression. This is a randomized, prospective, multicenter, double-blind study comparing NRX-101 to lurasidone over six weeks. The Principal Investigator is Prof. Andrew Nierenberg of
Top-line results are expected later this quarter.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for ketamine in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Cautionary Note Regarding Forward-Looking Statements
This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the
The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-completion-of-enrollment-of-its-phase-2b3-trial-of-nrx-101-in-suicidal-treatment-resistant-bipolar-depression-302039231.html
SOURCE NRx Pharmaceuticals
FAQ
What is the Phase 2b/3 study about?
How many patients were enrolled in the study?
What is the primary efficacy endpoint of the study?
Who is responsible for further development and commercialization costs for this program?
When are the top-line results expected?
